To sum up, this retrospective research demonstrates that thoracic, intraperitoneal injection or pericardial injection of DEX plus IL-2 is an effective and highly safe treatment for pediatric cancers with pleural effusion, ascites, and pericardial effusion. Here, IL2 is linked to pericardial effusion.